Metraipolis › archive › dc_91c071fe62ba
Targeting SIK2 with GRN-300 Potentiates Paclitaxel Efficacy in Triple-Negative Breast Cancer — Europe PMC PMID:42279425
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42279425
- DOI
- 10.3390/cancers18111843
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-31T19:50:47.356Z
- SHA-256 of the archived text
dcb845b9f4f87f594c3479c2d649fe3ff05c47b2c2a2e363283d393df335f98a- Stable URL of this page
https://metraipolis.com/documento/dc_91c071fe62ba
How to cite
Targeting SIK2 with GRN-300 Potentiates Paclitaxel Efficacy in Triple-Negative Breast Cancer — Europe PMC PMID:42279425 — Europe PMC (en), https://europepmc.org/article/MED/42279425 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_91c071fe62ba (Metraipolis archive dc_91c071fe62ba, sha256 dcb845b9f4f87f594c3479c2d649fe3ff05c47b2c2a2e363283d393df335f98a)
BibTeX
@misc{dc91c071fe62ba,
title = {Targeting SIK2 with GRN-300 Potentiates Paclitaxel Efficacy in Triple-Negative Breast Cancer — Europe PMC PMID:42279425},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42279425},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_91c071fe62ba; sha256 dcb845b9f4f87f594c3479c2d649fe3ff05c47b2c2a2e363283d393df335f98a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42279425. Agents can read the archived copy with the MCP tool read_document.